• Login
    View Item 
    •   DSpace Home
    • PROJECT REPORTS
    • SCHOOL OF MEDICAL & ALLIED SCIENCES
    • B.Pharma
    • View Item
    •   DSpace Home
    • PROJECT REPORTS
    • SCHOOL OF MEDICAL & ALLIED SCIENCES
    • B.Pharma
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Artificial Intelligence in Tissue Engineering for cardiovascular treatment

    Thumbnail
    View/Open
    Project Report (1.343Mb)
    Date
    2022-05
    Author
    SHAYAN, MD
    Dr. Ajay Pal Singh, (Supervisor)
    Metadata
    Show full item record
    Abstract
    The goal of this article is to evaluate how recent developments in fabrication techniques, genome editing, and machine learning are influencing the future of cardiac tissue engineering. AI algorithms have been used to diagnose, segment and reconstruct images, quality control, prognosis, Phen grouping, and scientific discovery in cardiology. AI is being used to automate electrocardiogram interpretation and patient categorization and prognosis. ML models can detect and compute a variety of cardiac parameters, including P and T waves, QRS complexes, heart rate, cardiac axis, ECG interval lengths, ST-changes, and common rhythm abnormalities. A 34-layer DNN has recently been developed that can recognise with more recall a human cardiologist. A variety of machine learning (ML), including SVMs, gradient boosting machines (GBMs), MLNNs, it is used to estimate patients' likelihood of experiencing an ischemic stroke. Transthoracic echocardiography provides instantaneous visualisation of the heart's structure, allowing for rapid diagnosis of structural abnormalities. An innovative method for calculating LVEF automatically from 2-D echocardiographic pictures using AI-learned pattern recognition. CRISPR/Cas9 systems used to design for cell of cardiac, with potential such as enhanced the avoidance of the body's immunological response. CRISPR/Cas9 technology can be used to improve cell homing, delete inactive genes, model cardiovascular disease, reduce immunogenicity, and protect hESC-derived allografts from immune rejection.
    URI
    http://10.10.11.6/handle/1/15095
    Collections
    • B.Pharma [63]

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV